Clinical trial to study the safety and efficacy of MBG453 given alone and in combination with PDR001 in adults with advanced cancer.
This is the first study done in humans for a new drug called MBG453. The purpose of the study is to learn about the safety, tolerability and antitumor activity of MBG453, when it is given IV either alone or in combination with PDR001 in adult patients with advanced cancers. In addition, blood tests will be done for pharmacokinetics (PK) to see how the body breaks down the drug.
To enroll or if you have questions about participation